Stock market analyst Rajesh Gupta of Fairwealth Securities has maintained 'buy' rating on Aurobindo Pharma Limited stock with a target of 1,130.

According to analyst, the interested investors can buy the stock above Rs 1085 with a strict stop loss of Rs 1069.90.

The stock of the company, on Sep 20, closed at Rs 1094.45 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1109.85 and a low of Rs 680 on BSE.

Current EPS & P/E ratio stood at 79.40 and 13.78 respectively.

Aurobindo Pharma Ltd declared that Medicines Control Council (MCC) South Africa has allotted 23 registrations to make and sell products in the South African market.

Now, the Aurobindo Pharma has a total of 48 products making up 91 registrations approved by Medicines Control Council.

Moreover, the company stated that it signed up licensing and supply pacts with AstraZeneca in order to deliver several solid amount and sterile products for growing market regions.

The contract is the second such deal for Aurobindo during the last 2 years.

A similar one with Pfizer was inked during March 2009.